Why we can’t ‘boost’ our way out of the Covid-19 pandemic for the long term
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Thursday
July 07, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
THURSDAY, JULY 07, 2022
Why we can’t ‘boost’ our way out of the Covid-19 pandemic for the long term

Coronavirus chronicle

Hindustan Times
17 April, 2022, 02:10 pm
Last modified: 18 April, 2022, 07:26 pm

Related News

  • 12.94 lakh people receive booster dose on 1st day of campaign 
  • Weeklong Covid booster campaign to begin on 4 June
  • Moderna seeks FDA authorisation for second Covid booster for all adults
  • Covid isolation time reduced to 10 days: DGHS
  • 7,41,265 people received booster doses: PM

Why we can’t ‘boost’ our way out of the Covid-19 pandemic for the long term

As immunologists studying immune response to infections and other threats, we are trying to better understand the vaccine booster-induced immunity against Covid-19

Hindustan Times
17 April, 2022, 02:10 pm
Last modified: 18 April, 2022, 07:26 pm
A health worker prepares a booster dose of a coronavirus disease (Covid-19) vaccine, as vaccinations jump in Italy after the government made inoculation mandatory for all workers, in Rome, Italy. Photo: Reuters
A health worker prepares a booster dose of a coronavirus disease (Covid-19) vaccine, as vaccinations jump in Italy after the government made inoculation mandatory for all workers, in Rome, Italy. Photo: Reuters

With yet another Covid-19 booster available for vulnerable populations in the US, many people find themselves wondering what the end game will be.

The mRNA vaccines currently used in the US against Covid-19 have been highly successful at preventing hospitalisation and death.

The Commonwealth Fund recently reported that in the US alone, the vaccines have prevented over 2 million people from dying and over 17 million from hospitalisation.

However, the vaccines have failed to provide long-term protective immunity to prevent breakthrough infections – cases of Covid-19 infection that occur in people who are fully vaccinated.

Because of this, the Centers for Disease Control and Prevention recently endorsed a second booster shot for individuals 50 years of age and older and people who are immunocompromised. Other countries including Israel, the UK and South Korea have also approved a second booster.

However, it has become increasingly clear that the second booster does not provide long-lasting protection against breakthrough infections. As a result, it will be necessary to retool the existing vaccines to increase the duration of protection in order to help bring the pandemic to an end.

As immunologists studying immune response to infections and other threats, we are trying to better understand the vaccine booster-induced immunity against Covid-19.

Activating longer-term immunity

It's a bit of a medical mystery: Why are mRNA vaccines so successful in preventing the serious form of Covid-19 but not so great at protecting against breakthrough infections? Understanding this concept is critical for stopping new infections and controlling the pandemic.

Covid-19 infection is unique in that the majority of people who get it recover with mild to moderate symptoms, while a small percentage get the severe disease that can lead to hospitalisation and death.

Understanding how our immune system works during the mild versus severe forms of Covid-19 is also important to the process of developing more targeted vaccines.

When people are first exposed to SARS-CoV-2 – the virus that causes Covid-19 – or to a vaccine against Covid-19, the immune system activates two key types of immune cells, called B and T cells. The B cells produce Y-shaped protein molecules called antibodies. The antibodies bind to the protruding spike protein on the surface of the virus. This blocks the virus from entering a cell and ultimately prevents it from causing an infection.

However, if not enough antibodies are produced, the virus can escape and infect the host cells. When this happens, the immune system activates what are known as killer T cells. These cells can recognise virus-infected cells immediately after infection and destroy them, thereby preventing the virus from replicating and causing widespread infection.

Thus, there is increasing evidence that antibodies may help prevent breakthrough infections while the killer T cells provide protection against the severe form of the disease.

Why booster shots?

The B cells and T cells are unique in that after they mount an initial immune response, they get converted into memory cells. Unlike antibodies, memory cells can stay in a person's body for several decades and can mount a rapid response when they encounter the same infectious agent. It is because of such memory cells that some vaccines against diseases such as smallpox provide protection for decades.

But with certain vaccines, such as hepatitis, it is necessary to give multiple doses of a vaccine to boost the immune response. This is because the first or second dose is not sufficient to induce robust antibodies or to sustain the memory B and T cell response.

This boosting, or amplifying of the immune response, helps to increase the number of B cells and T cells that can respond to the infectious agent. Boosting also triggers the memory response, thereby providing prolonged immunity against reinfection.

Covid vaccine boosters

While the third dose – or first booster – of Covid-19 vaccines was highly effective in preventing the severe form of Covid-19, the protection afforded against infection lasted for less than four to six months.

That diminished protection even after the third dose is what led the CDC to endorse the fourth shot of Covid-19 vaccine – called the second booster – for people who are immunocompromised and those aged 50 and older.

However, a recent preliminary study from Israel that has not yet been peer-reviewed showed that the second booster did not further boost the immune response but merely restored the waning immune response seen during the third dose. Also, the second booster provided little extra protection against Covid-19 when compared to the initial three doses.

So while the second booster certainly provides a small benefit to the most vulnerable people by extending immune protection by a few months, there has been considerable confusion over what the availability of the fourth shot means for the general population.

Frequent boosting and immune exhaustion

In addition to the inability of the current Covid-19 vaccines to provide long-term immunity, some researchers believe that frequent or constant exposure to foreign molecules found in an infectious agent may cause immune "exhaustion."

Such a phenomenon has been widely reported with HIV infection and cancer. In those cases, because the T cells "see" the foreign molecules all the time, they can get worn down and fail to rid the body of the cancer or HIV.

Evidence also suggests that in severe cases of Covid-19, the killer T cells may be exhibiting immune exhaustion and therefore be unable to mount a strong immune response. Whether repeated Covid-19 vaccine boosters can cause similar T cell exhaustion is a possibility that needs further study.

Role of adjuvants to boost vaccine-induced immunity Another reason why the mRNA vaccines have failed to induce sustained antibody and memory response may be related to ingredients called adjuvants. Traditional vaccines such as those for diphtheria and tetanus use adjuvants to boost the immune response. These are compounds that activate the innate immunity that consists of cells known as macrophages. These are specialized cells that help the T cells and B cells, ultimately inducing a stronger antibody response.

Because mRNA-based vaccines are a relatively new class of vaccines, they do not include the traditional adjuvants. The current mRNA vaccines used in the US rely on small balls of fat called lipid nanoparticles to deliver the mRNA. These lipid molecules can act as adjuvants, but how precisely these molecules affect the long-term immune response remains to be seen. And whether the current Covid-19 vaccines' failure to trigger strong long-lived antibody response is related to the adjuvants in the existing formulations remains to be explored.

While the current vaccines are highly effective in preventing severe disease, the next phase of vaccine development will need to focus on how to trigger a long-lived antibody response that would last for at least a year, making it likely that Covid-19 vaccines will become an annual shot.

Explainer / Health

Booster Dose / Covid second booster dose / Immune

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A complicated harvest.Photographer: Genya Savilov/AFP via Getty Images)
    A global famine is still an avoidable disaster
  • Boris Johnson quits as UK prime minister, dragged down by scandals
    Boris Johnson quits as UK prime minister, dragged down by scandals
  • Representational image. Picture: Pixabay
    Dhaka Wasa hikes water prices by 5%

MOST VIEWED

  • Vials of the Pfizer-BioNTech Covid-19 vaccine sit in a cooler before being thawed at a pop-up Covid-19 vaccination site in the Bronx borough of New York on Tuesday, Jan. 26, 2021. On Tuesday, Nov. 9, 2021, Pfizer asked US regulators to allow boosters of its Covid-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings. Photo: UNB/AP
    WTO faces new battle over Covid tests, drugs
  • Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), speaks during a news conference.(Reuters / File)
    Tracking new Omicron sub-variant BA.2.75 detected in India: WHO
  • A woman holding an umbrella walks on a pedestrian bridge by surveillance cameras, near Caopu in Shenzhen's Luohu district, Guangdong province, China July 5, 2022. REUTERS/David Kirton
    Hong Kong suspends flight bans as it eases Covid rules
  • (Reuters file image)
    Australia expands fourth Covid dose rollout amid fresh Omicron threat
  • A medical worker takes a swab sample at a nucleic acid testing station, following a coronavirus disease (COVID-19) outbreak, in Beijing, China, July 6, 2022. REUTERS/Thomas Peter
    Fresh Covid outbreaks put millions under lockdown in China
  • A medical staff in protective suit works at a nucleic acid testing laboratory of Nanjing First Hospital following a citywide mass testing for the coronavirus disease (COVID-19) in Nanjing, Jiangsu province, China July 24, 2021. cnsphoto via REUTERS/File Photo
    Covid and bust: China's private health system hurt by tough coronavirus controls

Related News

  • 12.94 lakh people receive booster dose on 1st day of campaign 
  • Weeklong Covid booster campaign to begin on 4 June
  • Moderna seeks FDA authorisation for second Covid booster for all adults
  • Covid isolation time reduced to 10 days: DGHS
  • 7,41,265 people received booster doses: PM

Features

Farsim is keen on listening to what his clients really want; in this profession attention is key. Photo: Noor-A-Alam

Making it as an audio engineer

11h | Pursuit
Illustration: TBS

Applystart: Helping students navigate the maze of foreign university applications

11h | Pursuit
The sea beach in Kuakata. Photo: Syed Mehedy Hasan

Five places in Southern Bangladesh you could visit via Padma Bridge

1d | Explorer
Genex Infosys Limited is the country's largest call centre with more than 2,000 seats and full-set equipment. Photo: Courtesy

How domestic demand made Genex Infosys a BPO industry leader

1d | Panorama

More Videos from TBS

New technology to benefit pilgrims at Hajj

New technology to benefit pilgrims at Hajj

56m | Videos
Load shedding is back

Load shedding is back

12h | Videos
Photo: TBS

Has Russia gained anything in its invasion of Ukraine?

13h | Videos
Behind the story of 'Aske Amar Mon Bhalo Nei'

Behind the story of 'Aske Amar Mon Bhalo Nei'

1d | Videos

Most Read

1
Photo: Collected
Africa

Uganda discovers gold deposits worth 12 trillion USD

2
TBS Illustration
Education

Universities may launch online classes again after Eid

3
Area-wise load shedding schedule will be announced: PM
Bangladesh

Area-wise load shedding schedule will be announced: PM

4
Padma Bridge opens up investment spree in south
Industry

Padma Bridge opens up investment spree in south

5
Build Dhaka East-West Elevated Expressway, relocate kitchen markets: PM
Bangladesh

Build Dhaka East-West Elevated Expressway, relocate kitchen markets: PM

6
File Photo: BSS
Energy

India pulls out of LoC funding for part of Rooppur power transmission work

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
A boat sails through the River Meghna carrying rice bran, a popular cattle feed, from a rice mill in Ashuganj to cattle markets. There are around 250 rice mills in Ashuganj that produce rice bran. The photo was taken recently. Photo: Rajib Dhar

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net